drugset / Trial / NCT04875364

Do Endotypes Predict Response and Sequelae in OSA Patients

NCT04875364

Phase 2 Completed 233 enrolled University of California, San Diego
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will investigate why some people have Obstructive Sleep Apnea (OSA) and how the underlying cause may relate to OSA manifestations (including sleepiness and high blood pressure) and response to different therapeutic approaches (ie CPAP, eszopiclone, and supplemental oxygen). Understanding why someone has OSA could affect how best to treat that individual, but may also have an impact on what problems the disease might cause.

Timeline

Start
2020-08-01
Primary completion
2026-02-11
Completion
2026-02-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Eszopiclone Small molecule 2 mg